At the current growth rate, diabetes threatens to overwhelm global health care systems. The need for innovation and leadership in preventing and managing diabetes has never been more important.
Our comprehensive diabetes menu offers outstanding quality and accuracy, enabling your lab to do more with less and clinicians to better evaluate diabetes treatment options to improve patient care.
Boost your lab’s productivity and efficiency with our Vitros® Diabetes Menu
Traceable to standardized materials and good correlation with other commercial assays.
Decreases the number of calibration events.
Highly specific antibodies and chemistry detection methods.
Optimizes reagent use and decreases waste.
No cuvettes to wash, no probes to clean, no risk of sample or reagent carry-over.
None-to-minimal cross-reactivity and minimal interferences.
Watch: Vitros® A1c Solution
See how we're revolutionizing the way labs help clinicians treat patients
Vitros® A1c solution: A breakthrough design in whole blood testing*
Break free from the complexities of whole blood A1c testing with our novel enzymatic Vitros A1c slides and built-in intelligent technologies so that you can report A1c results confidently while increasing productivity and efficiency.
*Not commercially available in the U.S., product availability subject to local regulatory requirements.
Vitros A1c slides have a multi-layered dry slide design that delivers exceptional performance. Certified by the National Glycohemoglobin Standardization Program (NGSP), it's free from hemoglobin variant interference.*
- Certified by NGSP2
- Highly specific enzyme for exceptional performance
- No interference from common hemoglobin variants3
- Reliable performance with good precision
- Standardized performance to Tosoh G8
- No reagent or sample carry-over with single-use disposable tips – no probes, tubes, cuvettes to wash
2. National Glycohemoglobin Standardization Program. Certified Methods. https://www.ngsp.org/certified.aspx
3. Up to HbS ≤ 41%, HbC ≤ 36%, HbD ≤ 41%, HbE ≤ 40%, HbA2 ≤ 7%, HbF ≤ 15%
- Increase testing capacity in Vitros MicroSlide format
- Test A1c in-between other routine tests
- Free up labor with Vitros® Automation Solutions track
*Up to HbS ≤ 41%, HbC ≤ 36%, HbD ≤ 41%, HbE ≤ 40%
- Insulin reagent
- C-peptide assay
- BHB
- Glycated serum protein
Vitros® Immunodiagnostic Products Insulin Reagent
The Vitros Insulin assay helps clinicians understand the cause of a patient’s hypoglycemia and differentiate between Type 1 and Type 2 diabetes.
The Vitros Insulin assay antibody is highly specific for insulin detection, with no cross-reactivity to C-peptide or proinsulin.1 Importantly, it has insignificant or no cross-reactivity to insulin analogs commonly used in diabetes treatment.
1Ding, Qian. Performance Comparison of Vitros Immunodiagnostic Products Insulin Assay. Ortho Clinical Diagnostics PR-03149. 2017
Vitros® Immunodiagnostics C-Peptide Assay
C-peptide testing provides a reliable assessment of beta-cell function and aids in differentiating Type 1, Type 2 diabetes and MODY.
Differentiating the diabetes type at clinical presentation is challenging, and clear answers can improve treatment decisions.
The Vitros C-Peptide assay uses an antibody highly specific for C-peptide detection with no significant cross-reactivities to insulin, proinsulin, glucagon, calcitonin or somatostatin.
β-Hydroxybutyrate LiquiColor® Assay*
Diabetic ketoacidosis (DKA) can manifest as the first sign of diabetes for patients with Type 1 and can occur in severe cases of hyperglycemia for patients with Type 2 diabetes.
The ß-Hydroxybutyrate LiquiColor assay quantitatively measures ß-hydroxybutyrate (BHB), the major ketone by-product from the body metabolizing fat stored in the liver when glucose is not available. The buildup of ketones in the blood can be fatal if left unchecked.
The ß-Hydroxybutyrate LiquiColor Assay is highly specific and is not susceptible to interferences for excellent performance on Vitros Systems. This life-saving test is ready when you are.
*MicroTip Partnership Assay. May not be available in all countries.
Glycated Serum Protein Assay*
Health conditions that alter the red blood cell lifespan make traditional HbA1c blood test methods unsuitable. Monitoring glycated serum proteins (GSP) provides clinicians with a short-term glycemic view of two to three weeks that’s useful in monitoring the effects of changes in diabetes treatment.
The Glycated Serum Protein assay uses an enzyme highly specific to glycated serum proteins. It does not have interference to reducing substances such as vitamins and bilirubin, unlike older colorimetric fructosamine assays.
*MicroTip Partnership Assay. May not be available in all countries.
Watch: Topics in HbA1c testing
Learn about the importance of HbA1c result standardization and how it is achieved by the National Glycohemoglobin Standardization Program (NGSP) to enable accurate HbA1c test results worldwide.
Presented by Randie R. Little, PhD, NGSP
Network Laboratory Coordinator and Director, Diabetes Diagnostic Laboratory University of Missouri.
